Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- CEA Process to Be Improved, but Operational Issues Remain: PhRMA/EFPIA
January 20, 2022
- JGA Chief Pledges to Restore Trust in Generics in 2022
January 14, 2022
- JPA Urges MHLW to Allow Access to List of Registered Pharmacies Carrying Lagevrio
January 14, 2022
- Osamu Kunii of Global Fund to Become New GHIT Fund CEO
January 13, 2022
- FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
- EFPIA Japan Taps Takeo Morooka as Director General
December 24, 2021
- Generic Use Rate Skids to 79.2% in July-September: JGA
December 24, 2021
- Japan Trade Groups Hail Progress in Reward for Innovation, but Fret Cost Disclosure Plans: FY2022 Reform
December 23, 2021
- INES Launches Cervical Cancer Awareness Project in Japan
December 10, 2021
- Study Group Launched by Drug Policy Veterans Pushes 6% Adjustment Rate
December 6, 2021
- JEMA Calls for Disclosure of Expected 3-Month Inventory Levels, Smaller Number of Companies per API
December 2, 2021
- Pharma, Wholesaler Leaders Hold 1st Meeting with PM Kishida
November 30, 2021
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
- JPMA Director Gets Sarcastic on MOF’s Data Presentation on Drug Costs
November 19, 2021
- Sales Reps in Japan Log Record Decline in FY2020, Down for 7 Consecutive Years
November 17, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- JPWA Vows to Boost Compliance after New Bid-Rigging Probe
November 12, 2021
- Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
- Japan No. 3 Originator Country in Global Top 100 Drug List in 2020: JPMA Think Tank
November 11, 2021
- PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…